Shares shifted sharply this week after a federal court forced the government to nearly double Clover Health's quality score on the plan covering almost all its members — a one-time legal win that unlocks millions in bonus payments but raises hard questions about whether the company can hold this ground on its own.
A Court Order, Not Clinical Improvement, Powered the Upgrade
CMS recalculated Clover's 2026 Star Rating to 4.5 stars, up from 3.5, after a federal judge in Georgia's Southern District granted summary judgment in the insurer's favor.
The upgraded PPO contract covers over 97% of Clover's members , making this effectively a company-wide event. But the rating wasn't earned through higher patient satisfaction scores or better outcomes — it was litigated. That distinction matters: before the ruling, Clover's enrollment-weighted average CMS quality rating was just 3.51 stars, well below the industry average of 4.02.
Bonus Payments Could Add Tens of Millions in 2027 Revenue
The rating impacts Payment Year 2027. In Medicare Advantage, plans rated four stars or higher get their benchmark — the government's per-member spending cap — increased by 5 percentage points. On top of that, plans at 4.5 stars or above keep 70% of the difference between their bid and that benchmark, versus 65% at the old 3.5-star level. For a company guiding $2.81–$2.92 billion in 2026 revenue with Adjusted EBITDA of $50–$70 million , even a modest per-member bonus across the entire PPO book could meaningfully improve margins.
Insiders Sold Into the Rally, and the CFO Already Left
Medicare Advantage CEO Jamie Reynoso sold 7,289 shares on June 11 — the day after the surge — for roughly $35,800.
The sale was under a pre-arranged trading plan , but it adds to a pattern: four insider selling transactions totaling ~$1.5 million in three months, with zero insider buys. Separately, the CFO departed effective March 30 , another overhang for investor confidence.
The Stock Ran Hard and Is Now Giving Some Back From $3.83 on June 5 to a close of $4.90 on June 11, CLOV gained roughly 28% in four sessions. Today's 6.2% pullback to $4.59 looks like textbook profit-taking. The open question: without sustained operational improvements in the metrics CMS actually measures, this court-won rating is a one-cycle boost, not a permanent fix.